Ready 8-Ks
5
Latest filing
September 11, 2026, 7:59 PM ET
Top materiality
0.60
Event mix
other ×2 · leadership ×2 · other_material ×1
Sentiment
1 pos · 0 neg · 4 neu
Recent 8-K filings for PLYX
Highest-materiality recent filing
Polaryx appoints Dr. Will Charlton as Chief Medical Officer; SOTERIA Phase 2 on track for Q4 2026
- Dr. Charlton appointed CMO effective Sept 1, 2026; brings 15+ years rare disease/pediatric drug development experience.
- Previously SVP Clinical Development at Tyra Biosciences; led Phase 2 rare disease trial; also CMO at Spruce Biosciences.
-
Polaryx appoints Dr. Will Charlton as Chief Medical Officer; SOTERIA Phase 2 on track for Q4 2026
Dr. Charlton appointed CMO effective Sept 1, 2026; brings 15+ years rare disease/pediatric drug development experience.
Materiality & sentiment trend
Max materiality 0.60 · Median 0.40 · Most common event other